MET and neoplasm: Particularly, Capmatinib, a c-MET kinase inhibitor approved by the FDA to treat metastatic NSCLC with specific mutations, has shown to promote an anti-tumor response independent of the tumor cell-intrinsic c-MET pathway blockade.